Effects of vitamin D on inflammatory state in patients with chronic kidney disease: A controversial issue.

What It Covers

This meta-analysis looks at Vitamin D, K2, Magnesium and Zinc.

This study aimed to conduct a meta-analysis of randomized controlled trials to assess the anti-inflammatory effects of vitamin D in patients with CKD.

Why It Was Studied

The anti-inflammatory effect of vitamin D in patients with chronic kidney disease (CKD) remains controversial.

Who the Included Studies Covered

The researchers searched Embase, Science Citation Index, Medline, Cochrane Central Register of Controlled Trials, and Clinical Trial Registries for randomized controlled trials that comparing vitamin D with control groups for inflammatory markers in patients with CKD.

Subgroup analysis was performed based on treatment duration (short-term treatment, long-term treatment), type of patients (predialysis CKD, dialysis, kidney transplant), 25(OH)D levels (25(OH)D deficiency or normal 25(OH)D), and methods of C-reactive protein (CRP) test (standard CRP test or high-sensitivity CRP [hs-CRP] test).

What Was Measured

Topics PubMed links to this paper include Anti-Inflammatory Agents, C-Reactive Protein, Renal Insufficiency, Chronic, Vitamin D, Vitamins and Randomized Controlled Trials as Topic.

The authors tagged it with the keywords chronic kidney disease, inflammation and meta-analysis.

What This Means in Plain Language

This is a meta-analysis of Vitamin D, K2, Magnesium and Zinc.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2023 (Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy), a journal based in Australia.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.